Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06991127 · ClinicalTrials.gov registry record · NA
Clinical Investigation of MAIA Microperimeter Device: Mesopic Normative Database Collection
A NA study of Healthy Eyes, sponsored by Centervue SpA.
- Recruiting
- Registry status
- NA
- Development phase
- 380
- Enrollment target
- 3
- Study locations
NCT06991127: Recruiting NA study of Healthy Eyes, sponsored by Centervue SpA.
NCT06991127 is a NA study of Healthy Eyes that is actively recruiting participants, run by Centervue SpA. The registered enrollment target is 380 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06991127, a NA study of Healthy Eyes, is actively recruiting participants, sponsored by Centervue SpA.
- RECRUITING
- Registry status
- NA
- Development phase
- 380 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this pre-market, multicentric cross-sectional study is to create a mesopic Normative Database for a new version of the MAIA device. Moreover, the study aims to evaluate MAIA safety and adverse events. These purposes will be achieved by collecting data of healthy subjects, who will undergo microperimetric examinations with the MAIA device during one single visit.
Primary Outcome
The reference normative values will be determined by using a linear regression model for Mean Sensitivity (MS) as a function of age. The 5th and 10th percentile values will be derived for each age, and will serve as age-adjusted normative data against which compare the MS computed during each test with MAIA
Conditions Studied
Interventions
- DEVICE MAIA
Study Locations (3)
Florida
- The Eye Care Institute - Fort Lauderdale
Western Australia
- UWA Eye Health Centre of Western Australia - Perth
Switzerland
- Universitätsspital Basel, Augenklinik - Basel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2026-06-01 |
| Phase | NA |
What NCT06991127 shows while recruiting
NCT06991127 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Healthy Eyes appearing as the primary indexed condition, and to 1 intervention - of which MAIA is the first listed.
NCT06991127 reports a single indexed study location in Florida, Western Australia, Switzerland.
Frequently Asked Questions
What is clinical trial NCT06991127 about?
NCT06991127 is a clinical study titled "Clinical Investigation of MAIA Microperimeter Device: Mesopic Normative Database Collection". The purpose of this pre-market, multicentric cross-sectional study is to create a mesopic Normative Database for a new version of the MAIA device. Moreover, the study aims to evaluate MAIA safety and adverse events. These purposes will be achieved by collecting data of healthy subjects, who will und...
What is the current status of trial NCT06991127?
This trial is currently recruiting. It is a NA study. The enrollment target is 380 participants. The study started on 2025-04-23. Estimated completion is 2026-06-01.
What conditions does trial NCT06991127 study?
This clinical trial studies the following conditions: Healthy Eyes.
What interventions are being tested in trial NCT06991127?
The interventions under investigation include: MAIA (DEVICE).
Who is sponsoring clinical trial NCT06991127?
This trial is sponsored by Centervue SpA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06991127 being conducted?
This trial has 3 study locations across Florida, Western Australia, Switzerland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Eyes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06991127's enrollment target sits among peer trials
380 273rd of 2000 higher than 1,727 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI